CytoDyn to Host Investor Webcast

VANCOUVER, Washington, April 23, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including metastatic triple-negative breast cancer (“mTNBC”) and colorectal cancer (“mCRC”), today announced it will host an investor webcast on April 30, 2026, at 1 p.m. PT, to provide a corporate and clinical update.

zur Originalmeldung